ment.' This conclusion was derived from the observation that when NSAID treatment in 11 patients was stopped there was a significant rise in creatinine clearance, a significant fall in serum creatinine, and a trend downwards in serum urea, compared with 11 patients who continued to receive NSAIDs, in whom no such changes were seen.
We have recently undertaken a study to investigate the effects of a new NSAID (tenoxicam) on renal function in a larger number of patients. The study comprised 40 patients (four male, 36 female; mean age (SEM) 72 (1-4) years) with RA or osteoarthritis and suffering from renal impairment as defined by a creatinine clearance of 25-80 ml/min. Patients stopped their NSAID treatment for a three day (n=27) or seven day (n= 13) washout period before starting tenoxicam (20 mg/day), which was continued for 12 weeks. All other drug treatment was continued as before such that low dose prednisolone was continued by seven patients and second line agents by eight. Renal function was monitored by measurement of creatinine clearance, serum creatinine, serum urea, and urine 1-Nacetylglucosaminidase/creatinine ratio at baseline (time of stopping current NSAID), week 0 (time of starting tenoxicam treatment) and weeks 4, 8, and 12 of tenoxicam treatment.
The 
